NCT01691326View on ClinicalTrials.gov

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose

0.25 mL dose, Intramuscular

BIOLOGICAL

Fluzone®; Influenza Virus Vaccine, No Preservative

0.5 mL dose, Intramuscular

Trial Locations (2)

40004

Bardstown

84124

Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01691326 - Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) | Biotech Hunter | Biotech Hunter